Kymera Therapeutics, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Kymera reported positive Phase 1 healthy volunteer data for KT-579 (IRF5 degrader) showing ≥90% median IRF5 degradation, robust biomarker suppression (88-98% inhibition of inflammatory cytokines), and favorable safety profile comparable to placebo. KT-621 (STAT6 degrader) BROADEN2 Phase 2b atopic dermatitis trial completed enrollment in October 2026 with topline data expected by year-end 2026; Phase 3 AD trial planned for mid-2027. Company has $1.6B cash with runway into 2029. Q3 2026 net loss was $132.0M vs. $82.2M in Q3 2025; R&D expenses increased to $128.5M (from $74.1M year-over-year) driven by STAT6 program expansion.
Why this rating
Positive clinical POC data on lead programs de-risks pipeline; BROADEN2 completion enables near-term readout. Event ~2.7% of market cap; material but not transformational at this stage.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.